Familial breast cancers without mutations in BRCA1 or BRCA2 have low cyclin E and high cyclin D1 in contrast to cancers in BRCA mutation carriers

Clinical Cancer Research

Volumn 14, Issue 7, 2008, Pages 1976-1983

  Aaltonen, Kirsimari ^a   Blomqvist, Carl ^a,b   Amini, Rose Marie ^b   Eerola, Hannaleena ^a   Aittomäki, Kristiina ^a   Heikkilä, Päivi ^a   Nevanlinna, Heli ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CYCLIN D1; CYCLIN E; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER GRADING; CONTROLLED STUDY; FAMILIAL CANCER; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE MICROARRAY; TUMOR VOLUME;

AGE OF ONSET; BREAST NEOPLASMS; CYCLIN D1; CYCLIN E; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; MUTATION; TUMOR MARKERS, BIOLOGICAL;

EID: 42249099170     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-4100     Document Type: Article

References (33)

1. Vehmanen P, Friedman LS, Eerola H, et al. Low proportion of BRCA1 and BRCA2 mutations in Finnish breast cancer families: evidence for additional susceptibility genes. Hum Mol Genet 1997;6:2309-15.
2. Eisinger F, Stoppa-Lyonnet D, Longy M, et al. Germ line mutation at BRCA1 affects the histoprognostic grade in hereditary breast cancer. Cancer Res 1996;56:471-4.
3. Johannsson OT, Idvall I, Anderson C, et al. Tumour biological features of BRCA induced breast and ovarian cancer. Eur J Cancer 1997;33:362-71.
4. Noguchi S, Kasugai T, Miki Y, Fukutomi T, Emi M, Nomizu T. Clinicopathologic analysis of BRCA1- or BRCA2-associated hereditary breast carcinoma in Japanese women. Cancer 1999;85:2200-5.
5. Lakhani SR, van de Vijver MJ, Jacquemeier J, et al. The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p5 3 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol 2002;20:2310-8.
6. Eerola H, Heikkila P, Tamminen A, Aittomaki K, Blomqvist C, Nevanlinna H. Histopathological features of breast tumours in BRCA1, BRCA2 and mutation-negative breast cancer families. Breast Cancer Res 2005;7:R93-100.
7. Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci US A 2003;100:8418-23.
8. Foulkes WD, Stefansson IM, Chapuis PO, et al. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst 2003;95:1482-5.
9. +) phenotype of BRCA1-relatedb reast cancer. Cancer Res 2004;64:830-5.
10. DiRenzo J, Signoretti S, Nakamura N, et al. Growth factor requirements and basal phenotype of an immortalized mammary epithelial cell line. Cancer Res 2002;62:89-98.
11. Lakhani SR, Reis-Filho JS, Fulford L, et al. Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res 2005;11:5175-80.
12. van der Groep P, Bouter A, van der Zanden A, et al. Distinction between hereditary and sporadic breast cancer on the basis of clinicopathological data. J Clin Pathol 2006;59:611-7.
13. Hedenfalk I, Duggan D, Chen Y, et al. Gene-expression profiles in hereditary breast cancer. N Engl J Med 2001;344:539-48.
14. Lakhani SR, Gusterson BA, Jacquemeier J, et al. The pathology of familial breast cancer: histological features of cancers in families not attributable to mutations in BRCA1 or BRCA2. Clin Cancer Res 2000;6:782-9.
15. Palacios J, Honrado E, Osorio A, et al. Immunohistochemical characteristics defined by tissue microarray of hereditary breast cancer not attributable to BRCA1 or BRCA2 mutations: differences from breast carcinomas arising in BRCA1 and BRCA2 mutation carriers. Clin Cancer Res 2003;9:3606-14.
16. Hedenfalk I, Ringner M, Ben-Dor A, et al. Molecular classification of familial non BRCA1/BRCA2 breast cancer. Proc Natl Acad Sci USA 2003;100:2532-7.
17. 1 cyclin-dependent kinases in the mammalian cell cycle. Curr Opin Cell Biol 2000;12:676-84.
18. 1-to-S phase transition. Mol Cell Biol 1995;15:2612-24.
19. Palacios J, Honrado E, Osorio A, et al. Phenotypic characterization of BRCA1 and BRCA2 tumors based in a tissue microarray study with 37 immunohistochemical markers. Breast Cancer Res Treat 2005;90:5-14.
20. Osin P, Gusterson BA, Philp E, et al. Predicted anti-oestrogen resistance in BRCA-associated familial breast cancers. Eur J Cancer 1998;34:1683-6.
21. Armes JE, Trute L, White D, et al. Distinct molecular pathogenesis of early-onset breast cancers in BRCA1 and BRCA2 mutation carriers: a population-based study. Cancer Res 1999;59:2011-7.
22. Vaziri SA, Krumroy LM, Elson P, et al. Breast tumor immunophenotype of BRCA1-mutation carriers is influenced by age at diagnosis. Clin Cancer Res 2001;7:1937-45.
23. Eerola H, Blomqvist C, Pukkala E, Pyrhonen S, Nevanlinna H. Familial breast cancer in southern Finland: how prevalent are breast cancer families and can we trust the family history reported by patients? Eur J Cancer 2000;36:1143-8.
24. Vahteristo P, Eerola H, Tamminen A, Blomqvist C, Nevanlinna H. A probability model for predicting BRCA1 and BRCA2 mutations in breast and breast-ovarian cancer families. Br J Cancer 2001;84:704-8.
25. Syrjakoski K, Vahteristo P, Eerola H, et al. Population-based study of BRCA1 and BRCA2 mutations in 1035 unselected Finnish breast cancer patients. J Natl Cancer Inst 2000;92:1529-31.
26. Kilpivaara O, Bartkova J, Eerola H, et al. Correlation of CHEK2 protein expression and c.1100delC mutation status with tumor characteristics among unselectedbr east cancer patients. Int J Cancer 2005;113:575-80.
27. Tanner M, Gancberg D, Di Leo A, et al. Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples. Am J Pathol 2000;157:1467-72.
28. Lassus H, Leminen A, Vayrynen A, et al. ERBB2 amplification is superior to protein expression status in predicting patient outcome in serous ovarian carcinoma. Gynecol Oncol 2004;92:31-9.
29. Tommiska J, Eerola H, Heinonen M, et al. Breast cancer patients with p53 Pro72 homozygous genotype have a poorer survival. Clin Cancer Res 2005;11:5098-103.
30. Ahlin C, Aaltonen K, Amini RM, Nevanlinna H, Fjallskog ML, Blomqvist C. Ki67 and cyclin A as prognostic factors in early breast cancer. What are the optimal cut-off values? Histopathology 2007;51:491-8.
31. Yoshida K, Miki Y. Role of BRCA1 and BRCA2 as regulators of DNA repair, transcription, andce ll cycle in response to DNA damage. Cancer Sci 2004;95:866-71.
32. 2/M checkpoint by activating Chk1 kinase upon DNA damage. Nat Genet 2002;30:285-9.
33. MacLachlan TK, Takimoto R, El-Deiry WS. BRCA1 directs a selective p53 dependent transcriptional response towards growth arrest and DNA repair targets. Mol Cell Biol 2002;22:4280-92.